Key result
Recurrent pregnancy loss linked to ~8-fold higher prevalence of anticardiolipin antibodies.
Why the study?
Anticardiolipin antibodies are found with increased prevalence in women with unexplained recurrent pregnancy loss but their impact on future pregnancy is not clearly known.
Does the presence of anticardiolipin antibodies increase the risk of adverse pregnancy outcomes in women with recurrent pregnancy loss?
Population
100 pregnant women including 50 with recurrent pregnancy loss and 50 healthy controls
Comparison
Pregnant women with recurrent pregnancy loss vs normal healthy pregnant women
Design
Prospective observational study
Authors
Loading...
Supports antibody testing in recurrent pregnancy loss evaluation; leaves open whether positivity alters management or outcomes.
Observational (n=100)
No
Does the presence of anticardiolipin antibodies increase the risk of adverse pregnancy outcomes in women with recurrent pregnancy loss?
Absolute Event Rate: 16% vs 2%
Anticardiolipin antibodies are more prevalent in women with recurrent pregnancy loss and are associated with lower live birth rates.
Malathi et al. (2017) conducted an observational in Recurrent pregnancy loss (n=100). History of recurrent pregnancy loss vs. Healthy pregnant women with no history of pregnancy loss was evaluated on Prevalence of anticardiolipin antibodies (ACA). The prevalence of anticardiolipin antibodies was 16% in women with a history of recurrent pregnancy loss compared to 2% in healthy pregnant women.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: